I have a flow system

Chapter 233 Aiying Biotechnology, which is not short of money---CRISPR gene drug clinical project ap

Chapter 233 Aiying Biotechnology, which is not short of money - CRISPR gene drug clinical project approval
Professor Li walked into the coffee shop with the latest issue of The Lancet.He invited a few colleagues to chat, and also exchanged recent research progress by the way.He found a corner spot, sat down and waited for the others to arrive.

Less than 5 minutes after sitting down, Dr. Wang and Dr. Zhang also walked in.They are all old friends of Professor Li and well-known medical experts in China.After they saw Professor Li, they simply greeted each other and sat opposite him.

"This is the latest issue of The Lancet. Is there any new discovery?" Dr. Wang asked.

"I saw an interesting article about the treatment of advanced lung cancer with CRISPR gene-editing drugs," said Dr. Wang.

"Oh? Gene-editing drugs? How far has the related research progressed? Which company's project?" Dr. Zhang asked curiously.

"The effect is not bad, you can see for yourself." Professor Li directly handed over the Lancet magazine in his hand.

Dr. Zhang took it directly and looked at it, and Dr. Wang on the side also moved his head to follow it.

"A customized lung cancer drug based on CRISPR gene editing technology has shown significant anti-cancer effects in animal experiments. This drug can precisely repair or eliminate mutations in cancer cells according to the genetic characteristics of each patient's tumor Or abnormal genes, so as to achieve the purpose of killing cancer cells or preventing their proliferation and metastasis.

At present, animal experiments on mice and rats have been completed, and human clinical trials are being applied for.

In animal experiments, the drug was compared with conventional chemotherapy drugs.The results showed that the drug could significantly and effectively reduce the volume of transplanted tumors of lung cancer cells and prolong the survival time of animals.

In experiments on mice, after four weeks of treatment, the average tumor volume in the drug group was 4 cubic millimeters, compared with 50.6 cubic millimeters in the chemotherapy group and 179.4 cubic millimeters in the control group.Compared with the chemotherapy group and the control group, the drug group had statistically significant differences (P<248.7).

In rat experiments, after eight weeks of treatment, the average tumor volume in the drug group was 8 cubic millimeters, compared with 68.3 cubic millimeters in the chemotherapy group and 302.5 cubic millimeters in the control group.Compared with the chemotherapy group and the control group, the drug group had statistically significant differences (P<412.6).

In addition, in the mouse experiment, the average survival time of the drug group was 72 days, compared with 48 days in the chemotherapy group and 38 days in the control group."

Dr. Zhang and Dr. Wang looked up one after another after reading it, but they noticed the company name at the end.

"Aiying Biological Company? Why do I look at this name and feel a bit like the Aiying Biological Company in our country." Dr. Zhang muttered subconsciously.

Dr. Wang also nodded in agreement, because during this period of time, when he was leisurely, he could often see some news videos from self-media channels pushing him the latest research results of this Aiying biology.

So when I saw this name at this moment, the first thing that came to my mind was the name of this domestic company.

"Well, yes. That's why I asked you to come here this time." Professor Li nodded.

"Oh? What do you mean?" Dr. Wang looked at Professor Li after speaking.

But Dr. Zhang asked with a smile. "It seems that you don't go to the Three Treasures Hall if you don't have anything to do. Let me tell you why you, a busy person, suddenly invited a guest for dinner."

"This project was done by our domestic Aiying Biotech, and the person in charge of the project is my college classmate." Professor Li did not hide anything, and told all the details, and directly took out two relevant details and handed them directly to two people.

The main reason for choosing these two friends of mine is that they are the top doctors in related fields in China.

Although he is not a director or anything, he already has the title of deputy director, and he is still in China's top hospitals like Xiehe Cancer Hospital. There is no shortage of medical ethics, medical skills, and patients.

Dr. Wang and Dr. Zhang are also distractedly studying the specific details at the moment. This drug is simply a customized drug.

"In the first step, tumor tissue samples are taken from the patient, and whole exome sequencing and HLA typing are performed to determine the patient's TSA and its corresponding HLA-restricted peptides.

In the second step, the corresponding gRNA is designed and synthesized according to the patient's TSA and its HLA-restricted peptide, and combined with the Cas9 protein to form an RNP complex.

In the third step, peripheral blood mononuclear cells (PBMC) are collected from the patient, and CD8+ T lymphocytes are isolated.

The fourth step is to transfect the RNP complex into CD8+ T lymphocytes, and use the CRISPR-Cas9 system to insert the TSA-HLA-restricted peptide coding sequence into the TCRα chain constant region gene, so that CD8+ T lymphocytes express specificity TCR, and can recognize and kill tumor cells expressing the same TSA-HLA restricted peptide.

Finally, the edited and expanded CD8+ T lymphocytes were reinfused back to the patient as a personalized CRISPR-Cas9 gene editing immunotherapy. "

"This personalized solution is really good, but expensive," Dr. Wang couldn't help but joked.

When top doctors choose which drug clinical trials to participate in, they are not completely arbitrary or completely passive, but make decisions based on comprehensive consideration of many factors.

In general, doctors will cooperate with well-known pharmaceutical companies or institutions because of their own wishes, or the impact of the hospital's index policies, or personal career development.

"The innovation is good, it also has good potential value, and the social demand is also great. The only problem may be that the strength of pharmaceutical companies is average." Dr. Zhang read it at this time and also commented.

"The specific pricing, we have to wait until it goes on the market to find out, and it's not clear yet. But I think it will definitely be much cheaper than foreign ones. As for the strength of Aiying Biotech, if we only consider the establishment time, such as drugs that have been on the market From a perspective, Aiying Bio is not even as good as small factories in some places, but small factories are not willing to spend money on multiple projects at the same time and invest a large amount of research and development expenses." Professor Li explained patiently.

"Old Li, it seems that your classmates have told you a lot of inside information? Let's talk about it, so we can understand." Both Dr. Wang and Dr. Zhang looked at Professor Li.

"Well, they told me some things, but I'll declare in advance that what I said next is just a retelling."

"When the boss of Aiying Biology, that young man Wu Zhou, recruited my classmate, one of the conditions he gave was that the annual research and development expenses support should not be less than 1 million yuan. The second condition is that there is no limit. For research, the only requirement is that the research project must be a breakthrough in innovative product research.”

"Last weekend, I chatted with my classmate about work, and according to his answer, Aiying Biotech has exceeded its promise to him, and said without hesitation that Aiying Biology is the best researcher he has ever worked in. Institutions, none of them."

"In addition, as far as he knows and has come into contact with, Aiying Biotech is currently researching in many fields, covering innovative drugs and biological agents with major medical needs such as mask virus, cancer, cardiovascular, and nervous system. In addition, gene therapy The application of cutting-edge technologies such as mRNA therapy and mRNA therapy is also a lot of investment, and many of them are breakthrough innovative products. I think there will be more and more related clinical projects in the future. "Professor Li said with a smile, saying that these cutting-edge people's scientific research projects when.

Dr. Wang and Dr. Zhang also had their pupils slightly dilated, which sounds unreal.
"What stage are they in this clinical project?" Dr. Wang finally said, the process of a clinical project can be roughly divided into the following stages: pre-project approval, project approval, ethics review, review by the Genetics Office, contract signing, center start-up, clinical After the observation and experimentation, the project may take 3 to 6 months from project approval to launch.

"The project has just been approved, but my classmate said that in the later clinical process of this project, if the effect is good, each cooperating doctor can make decisions independently and increase the number of clinical recruitment. Charitable drug donations"

"Hiss, it's really not short of money." Dr. Zhang and Dr. Wang gasped at the same time.

(End of this chapter)

Tap the screen to use advanced tools Tip: You can use left and right keyboard keys to browse between chapters.

You'll Also Like